Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

TH-302 Shows Non-Significant Improvement in OS for Advanced Pancreatic Cancer

September 17th 2012

A secondary analysis of a combination of an investigational hypoxia-targeted agent called TH-302 with gemcitabine slightly improved overall survival, but the results were not statistically significant.

Trials in Progress Poster Session

September 10th 2012

The Trials in Progress Poster Session at the ASCO Annual Meeting, now in its third year, is intended to stimulate discussion in the oncology community about ongoing clinical trials and to promote collaboration.

Colonoscopy Linked With Lower Risk of Colorectal Cancer Mortality

August 24th 2012

Colonoscopy is effective for the prevention of colorectal cancer deaths, according to the results of a large, population-based, case-control study.

Tivantinib Achieves Advantage for Patients With HCC

August 9th 2012

Tivantinib has demonstrated statistically significant improvements in time to progression and overall survival versus placebo among patients with unresectable hepatocellular carcinoma.

Regorafenib Extends Survival in Colorectal Cancer, Delays Disease Progression in GIST

August 7th 2012

The oral multikinase inhibitor regorafenib extended OS in patients with metastatic colorectal cancer and improved PFS in patients with gastrointestinal stromal tumors.

FDA Approves Aflibercept for Metastastic Colorectal Cancer

August 3rd 2012

The FDA announced that aflibercept has been approved to treat metastatic colorectal cancer when given in combination with the FOLFIRI chemotherapy regimen.

Research Further Supports Aflibercept Benefit in Metastatic Colorectal Cancer

July 30th 2012

The phase III VELOUR trial demonstrated that the addition of aflibercept to FOLFIRI improved overall survival compared with placebo plus FOLFIRI in patients with metastatic colorectal cancer.

Dr. Yuan on Tivantinib for Hepatocellular Carcinoma

July 18th 2012

Dr. RuiRong Yuan, from Daiichi Sankyo, on the Efficacy of Tivantinib for Patietns With Hepatocellular Carcinoma.

Hereditary Colon Cancer: Which Patients Are at High Risk?

July 16th 2012

Colon cancer is equally as likely as breast and ovarian cancer to be hereditary (approximately 10% of cases, overall) and there are many different genes responsible for these cases.

FDA Approves Cetuximab Plus FOLFIRI for Metastatic Colorectal Cancer

July 10th 2012

The FDA has approved cetuximab in combination with the FOLFIRI regimen as a first-line treatment for patients with mCRC who express EGFR and wild-type KRAS mutations.

Antibody Gets High Marks in Small Hepatocellular Carcinoma Trial

July 6th 2012

Three-fourths of patients with advanced hepatocellular carcinoma associated with hepatitis C infection achieved disease control with antibody therapy directed at a T-cell antigen.

Cetuximab Fails to Extend PFS in Advanced Gastric Cancer

July 5th 2012

The phase III EXPAND trial of cetuximab in combination with standard chemotherapy for patients with advanced gastric adenocarcinoma failed to show a significant improvement in progression-free survival.

Diabetes Drug Emerges as Potential Therapy in Multiple Cancers

July 2nd 2012

Four studies reflected the growing interest in-and the volume of evidence for-using the diabetes drug metformin as a potential cancer therapy.

Dr. Arnold on Second-Line Avastin Continuation for mCRC

June 19th 2012

Dr. Dirk Arnold, from the University Cancer Center Hamburg, Germany, on Second-Line Bevacizumab Continuation Therapy for Metastatic Colorectal Cancer

Finding Time: A Day in the Life of an Academic Oncologist

June 15th 2012

We all have to balance competing demands on our time. But as an academic oncologist, I have to keep a foot in 2 worlds, research and clinical, while still keeping my balance.

Dr. Wood on Family Histories and Genetic Counseling

June 5th 2012

Dr. Marie Wood, from the University of Vermont, on Family Histories and Genetic Counseling for Breast and Colorectal Cancers.

Pilot Study Evaluates a Proposed Quality Measure for Family History Collection and Genetic Testing Referral

June 5th 2012

Only half of those with breast cancer and one-quarter of those with colon cancer were referred for genetic counseling or testing by their physicians.

Dr. Demetri Discusses Regorafenib for GIST Patients

June 4th 2012

Dr. George Demetri, from Dana-Farber Cancer Institute, Discusses Regorafenib for Patients with GIST Trial Results.

Regorafenib Offers New Hope for Patients With Treatment-Resistant GIST

June 4th 2012

The oral multikinase inhibitor regorafenib reduced the risk of disease progression by 73% in patients with gastrointestinal stromal tumors who had exhausted all other treatment options.

Bevacizumab Plus Second-Line Chemotherapy Extends Survival in Advanced Colorectal Cancer Patients

June 3rd 2012

Bevacizumab plus chemotherapy as a second-line treatment for metastatic colorectal cancer improved survival among patients whose disease had progressed after first-line combination therapy with bevacizumab.